Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors
Amr K.A. Bass, El-Shimaa M. Nageeb, Mona S. El‐Zoghbi, et al.
Bioorganic Chemistry (2021) Vol. 119, pp. 105564-105564
Closed Access | Times Cited: 22

Showing 22 citing articles:

Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 72
Evaluation of the anti-proliferative activity of 2-oxo-pyridine and 1′H-spiro-pyridine derivatives as a new class of EGFRWt and VEGFR-2 inhibitors with apoptotic inducers
Reham R. Raslan, Yousry A. Ammar, Sawsan A. Fouad, et al.
RSC Advances (2023) Vol. 13, Iss. 15, pp. 10440-10458
Open Access | Times Cited: 23
Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles
Li Chen, Wuyu Mao, Changyu Ren, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 1, pp. 38-64
Closed Access | Times Cited: 11
Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors
G. Sivaiah, M.S. Raghu, S. Prasad, et al.
Journal of Molecular Structure (2024) Vol. 1309, pp. 138223-138223
Closed Access | Times Cited: 11
Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities
Asmaa Ahmed, Mamdouh F. A. Mohamed, Rasha M. Allam, et al.
Bioorganic Chemistry (2022) Vol. 129, pp. 106171-106171
Closed Access | Times Cited: 28
Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition
Mohammed M. Amin, Gamal El‐Din A. Abuo‐Rahma, Montaser Sh. A. Shaykoon, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106444-106444
Closed Access | Times Cited: 15
Design, Synthesis and Mechanistic Study of New Dual Targeting HDAC/Tubulin Inhibitors
Mona S. El‐Zoghbi, Amr K.A. Bass, Gamal El‐Din A. Abuo‐Rahma, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 7, pp. 601-622
Open Access | Times Cited: 5
Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article
Nardin Wagih, Islam M. Abdel-Rahman, Nawal El‐Koussi, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 966-1010
Open Access
Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents
Eman A. Ahmed, Mamdouh F. A. Mohamed, Omran A. Omran
RSC Advances (2022) Vol. 12, Iss. 39, pp. 25204-25216
Open Access | Times Cited: 20
Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study
Samy Mohamady, Ahmed Khalil, Bassem H. Naguib, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 106988-106988
Closed Access | Times Cited: 9
Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAFV600E with promising antiproliferative properties
Hesham A. Abou‐Zied, Eman A. M. Beshr, Hesham A. M. Gomaa, et al.
Archiv der Pharmazie (2022) Vol. 356, Iss. 4
Closed Access | Times Cited: 15
Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways
Lamya H. Al-Wahaibi, Hesham A. Abou‐Zied, Mohamed Hisham, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6586-6586
Open Access | Times Cited: 8
Recent developments of hydroxamic acid hybrids as potential anti-breast cancer agents
Xinran Cao, Yufeng Gong
Future Medicinal Chemistry (2024) Vol. 16, Iss. 5, pp. 469-492
Open Access | Times Cited: 2
A review: Biological activities of novel cyanopyridine derivatives
Yurou Wu, Tao Wu, Yong Huang
Archiv der Pharmazie (2023) Vol. 356, Iss. 7
Closed Access | Times Cited: 7
N-(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity
Dimitrios Triantafyllos Gerokonstantis, Christiana Mantzourani, Dimitrios Gkikas, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14357-14376
Closed Access | Times Cited: 7
Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors
Ying‐Chao Duan, Tong Yu, Linfeng Jin, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115367-115367
Closed Access | Times Cited: 6
Cyanopyridinone- and Cyanopyridine-Based Cancer Cell Pim-1 Inhibitors: Design, Synthesis, Radiolabeling, Biodistribution, and Molecular Modeling Simulation
Basem Mansour, Yomna A. Salem, Khaled M. Attallah, et al.
ACS Omega (2023) Vol. 8, Iss. 22, pp. 19351-19366
Open Access | Times Cited: 5
Nicotinonitrile as an essential scaffold in medicinal chemistry: an updated review (2015– present)
Heba Hassan, Mohamed Hisham, M.S. Osman, et al.
Journal of advanced Biomedical and Pharmaceutical Sciences (2022) Vol. 6, Iss. 1, pp. 1-11
Open Access | Times Cited: 9
Design and Synthesis of Potent Anticancer Agents Using Coumarin‐Quinazolinone Based Scaffolds: Exploration of ADME Properties and Molecular Docking Studies
Vardhaman Babagond, Kariyappa S. Katagi, Mahesh Akki, et al.
ChemistrySelect (2024) Vol. 9, Iss. 17
Closed Access | Times Cited: 1
Cs2CO3‐Promoted Alkylation of 3‐Cyano‐2(1H)‐pyridones: Anticancer Evaluation and Molecular Docking
Kevin Salamanca-Perdigón, Diana Hurtado-Rodríguez, Jaime Portilla, et al.
ChemPlusChem (2024)
Closed Access | Times Cited: 1
Design, synthesis, and anti-breast cancer activity evaluation of novel 3-cyanopyridine derivatives as PIM-1 inhibitors
Bahgat R. M. Hussein, Hayam H. Mohammed, Eman A. Ahmed, et al.
Molecular Diversity (2024)
Open Access | Times Cited: 1
Sulfonylhydrazide Derivatives as Potential Anti-cancer Agents: Synthesis, In Vitro and In Silico Studies
Kholoud M Ibrahim, Doaa M. Elsisi, Yousry A. Ammar, et al.
The Protein Journal (2024)
Closed Access
Page 1

Scroll to top